Why the study?
Does benazepril monotherapy effectively control blood pressure without adverse renal hemodynamic effects in hypertensive patients with mild to moderate renal dysfunction?
Does benazepril monotherapy effectively control blood pressure without adverse renal hemodynamic effects in hypertensive patients with mild to moderate renal dysfunction?
Benazepril monotherapy effectively controls blood pressure without adverse renal hemodynamic effects in hypertensive patients with moderate renal insufficiency.
Answers are grounded in this paper and cite their sources.
May support benazepril in select renal impairment cases; leaves open need for controlled trials.
Nine hypertensive patients with mild to moderate renal dysfunction were entered into a protocol to assess the blood pressure, humoral and renal effects of the angiotensin converting enzyme inhibitor, Benazepril (CGS14824A, 2 to 20 mg twice daily) in patients with hypertension and moderate renal insufficiency (mean creatinine clearance 56 ml/min/1.73 m2). Specifically monitored, prior to and following 12 weeks of Benazepril monotherapy, were plasma renin activity and plasma aldosterone, the clearances of creatinine, Tc99m-diethylenetriaminepentaacetic acid (TC99m-DTPA) and para-amino-hippurate, and the 24-hour urinary excretion of protein. Blood pressure was well controlled. Plasma renin activity was stimulated, and plasma aldosterone was suppressed. Mean serum potassium increased from 3.9 to 4.2 mEq/L. Benazepril monotherapy had no adverse renal hemodynamic effect. Benazepril appears to be an effective antihypertensive agent in hypertensive patients with moderately impaired renal function.
No takes yet. Share an insight, caveat, or question.
Reams et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: